vs
Aclarion, Inc.（ACON）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Aclarion, Inc.的47536.6倍（$878.4M vs $18.5K）。EXACT SCIENCES CORP净利率更高（-9.8% vs -10223.7%，领先10214.0%）。Aclarion, Inc.同比增速更快（80.6% vs 23.1%）。过去两年Aclarion, Inc.的营收复合增速更高（35.2% vs 17.4%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
ACON vs EXAS — 直观对比
营收规模更大
EXAS
是对方的47536.6倍
$18.5K
营收增速更快
ACON
高出57.5%
23.1%
净利率更高
EXAS
高出10214.0%
-10223.7%
两年增速更快
ACON
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $878.4M |
| 净利润 | $-1.9M | $-86.0M |
| 毛利率 | 9.7% | 70.1% |
| 营业利润率 | -10785.8% | -9.4% |
| 净利率 | -10223.7% | -9.8% |
| 营收同比 | 80.6% | 23.1% |
| 净利润同比 | 5.0% | 90.1% |
| 每股收益（稀释后） | $1.39 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONEXAS
| Q4 25 | $18.5K | $878.4M | ||
| Q3 25 | $18.9K | $850.7M | ||
| Q2 25 | $19.3K | $811.1M | ||
| Q1 25 | $19.0K | $706.8M | ||
| Q4 24 | $10.2K | $713.4M | ||
| Q3 24 | $14.4K | $708.7M | ||
| Q2 24 | $11.0K | $699.3M | ||
| Q1 24 | $10.1K | $637.5M |
净利润ACONEXAS
| Q4 25 | $-1.9M | $-86.0M | ||
| Q3 25 | $-1.7M | $-19.6M | ||
| Q2 25 | $-1.6M | $-1.2M | ||
| Q1 25 | $-2.0M | $-101.2M | ||
| Q4 24 | $-2.0M | $-864.6M | ||
| Q3 24 | $-1.4M | $-38.2M | ||
| Q2 24 | $-1.2M | $-15.8M | ||
| Q1 24 | $-2.4M | $-110.2M |
毛利率ACONEXAS
| Q4 25 | 9.7% | 70.1% | ||
| Q3 25 | 23.2% | 68.6% | ||
| Q2 25 | 26.6% | 69.3% | ||
| Q1 25 | -23.6% | 70.8% | ||
| Q4 24 | -100.9% | 69.0% | ||
| Q3 24 | -48.1% | 69.4% | ||
| Q2 24 | -112.3% | 69.8% | ||
| Q1 24 | -92.6% | 70.0% |
营业利润率ACONEXAS
| Q4 25 | -10785.8% | -9.4% | ||
| Q3 25 | -9666.2% | -3.0% | ||
| Q2 25 | -8988.6% | -0.3% | ||
| Q1 25 | -7856.0% | -13.6% | ||
| Q4 24 | -17652.7% | -122.8% | ||
| Q3 24 | -8995.3% | -5.6% | ||
| Q2 24 | -10350.6% | -3.8% | ||
| Q1 24 | -12609.3% | -16.7% |
净利率ACONEXAS
| Q4 25 | -10223.7% | -9.8% | ||
| Q3 25 | -9008.0% | -2.3% | ||
| Q2 25 | -8285.9% | -0.1% | ||
| Q1 25 | -10728.4% | -14.3% | ||
| Q4 24 | -19444.6% | -121.2% | ||
| Q3 24 | -9482.7% | -5.4% | ||
| Q2 24 | -11285.0% | -2.3% | ||
| Q1 24 | -23720.6% | -17.3% |
每股收益（稀释后）ACONEXAS
| Q4 25 | $1.39 | $-0.45 | ||
| Q3 25 | $-2.93 | $-0.10 | ||
| Q2 25 | $-2.75 | $-0.01 | ||
| Q1 25 | $-9.32 | $-0.54 | ||
| Q4 24 | $-809.36 | $-4.69 | ||
| Q3 24 | $-1321.49 | $-0.21 | ||
| Q2 24 | $-1362.83 | $-0.09 | ||
| Q1 24 | $-3985.22 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.8M | $2.4B |
| 总资产 | $13.7M | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONEXAS
| Q4 25 | $12.0M | $964.7M | ||
| Q3 25 | $11.3M | $1.0B | ||
| Q2 25 | $12.8M | $858.4M | ||
| Q1 25 | $14.8M | $786.2M | ||
| Q4 24 | $453.7K | $1.0B | ||
| Q3 24 | $1.3M | $1.0B | ||
| Q2 24 | $1.2M | $946.8M | ||
| Q1 24 | $2.1M | $652.1M |
股东权益ACONEXAS
| Q4 25 | $12.8M | $2.4B | ||
| Q3 25 | $12.5M | $2.5B | ||
| Q2 25 | $14.2M | $2.5B | ||
| Q1 25 | $15.8M | $2.4B | ||
| Q4 24 | $970.1K | $2.4B | ||
| Q3 24 | $2.5M | $3.2B | ||
| Q2 24 | $1.6M | $3.2B | ||
| Q1 24 | $2.5M | $3.1B |
总资产ACONEXAS
| Q4 25 | $13.7M | $5.9B | ||
| Q3 25 | $13.2M | $5.9B | ||
| Q2 25 | $14.8M | $5.8B | ||
| Q1 25 | $16.5M | $5.7B | ||
| Q4 24 | $2.1M | $5.9B | ||
| Q3 24 | $3.2M | $6.7B | ||
| Q2 24 | $3.1M | $6.7B | ||
| Q1 24 | $3.7M | $6.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | — | $120.4M |
| 自由现金流率自由现金流/营收 | — | 13.7% |
| 资本支出强度资本支出/营收 | — | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流ACONEXAS
| Q4 25 | $-1.6M | $151.7M | ||
| Q3 25 | $-1.2M | $219.9M | ||
| Q2 25 | $-1.9M | $89.0M | ||
| Q1 25 | $-2.5M | $30.8M | ||
| Q4 24 | $-922.9K | $47.1M | ||
| Q3 24 | $-1.1M | $138.7M | ||
| Q2 24 | $-1.1M | $107.1M | ||
| Q1 24 | $-2.2M | $-82.3M |
自由现金流ACONEXAS
| Q4 25 | — | $120.4M | ||
| Q3 25 | $-1.2M | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
自由现金流率ACONEXAS
| Q4 25 | — | 13.7% | ||
| Q3 25 | -6164.6% | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
资本支出强度ACONEXAS
| Q4 25 | — | 3.6% | ||
| Q3 25 | 38.6% | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 0.0% | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
